Oyebanji, Oladayo A.
Sundheimer, Nicholas
Ragavapuram, Vaishnavi
Wilson, Brigid M.
Abul, Yasin
Gravenstein, Stefan
Bosch, Jürgen
King, Christopher L.
Canaday, David H. http://orcid.org/0000-0001-5503-7888
Funding for this research was provided by:
Division of Intramural Research, National Institute of Allergy and Infectious Diseases (AI129709-03S1)
Centers for Disease Control and Prevention (200-2016-91773)
U.S. Department of Veterans Affairs (BX005507-0)
Article History
Received: 22 February 2024
Accepted: 17 May 2024
First Online: 25 May 2024
Declarations
:
: Stefan Gravenstein (S. G.) and David H. Canaday (D. H. C.) are recipients of investigator-initiated grants to their universities from Pfizer to study pneumococcal vaccines, Moderna to study respiratory infection surveillance, and Sanofi Pasteur and Seqirus to study influenza vaccines, and S.G. from Genentech on influenza antivirals. S. G. also receives consulting fees from GlaxoSmithKline, Icosavax, Janssen, Merck, Moderna, Novavax, Pfizer, Reviral, Sanofi, Seqirus, and Vaxart, and has received fees for speaking for Janssen, Moderna, Sanofi, and Seqirus.